Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.57 |
| ▸ | ATR | Q13535 | 10/20 | 0.56 |
| ▸ | PRKDC | P78527 | 4/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28324236 | 0.87 | IKBKB (0.58) | ASIC3ATRPRKDCIKBKBATM | |
| SCHEMBL318797 | 0.86 | ATR (0.68) | ATRPRKDCIKBKBATMCYP3A4 | |
| SCHEMBL6987949 | 0.84 | IKBKB (0.51) | ASIC3ATRPRKDCIKBKBATM | |
| SCHEMBL22712451 | 0.83 | IKBKB (0.47) | ASIC3ATRPRKDCIKBKBATM | |
| SCHEMBL29368281 | 0.83 | IKBKB (0.47) | ASIC3ATRPRKDCIKBKBATM | |
| SCHEMBL336653 | 0.83 | ATR (0.53) | ASIC3ATRPRKDCIKBKBATM | |
| SCHEMBL26986900 | 0.81 | IKBKB (0.48) | ASIC3ATRPRKDCIKBKBLDHA | |
| SCHEMBL28918651 | 0.79 | ALDH1A1 (0.56) | ATRPRKDCIKBKBLDHA | |
| SCHEMBL5684569 | 0.79 | ATR (0.63) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL24248259 | 0.78 | ATR (0.67) | ATRPRKDCIKBKBATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | ASIC3 2273/4885ATR 4853/4885PRKDC 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.